122 related articles for article (PubMed ID: 1674155)
1. [Therapeutic treatment with neuroleptics. II: Subjective mechanisms of effect, compliance and consequences for treatment strategy].
Krausz M; Sorgenfrei T
Psychiatr Prax; 1991 Jan; 18(1):14-20. PubMed ID: 1674155
[TBL] [Abstract][Full Text] [Related]
2. Subjective response to neuroleptics: the effect of a questionnaire about neuroleptic side effects.
Taira M; Hashimoto T; Takamatsu T; Maeda K
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1139-42. PubMed ID: 16765499
[TBL] [Abstract][Full Text] [Related]
3. [Therapeutic treatment with neuroleptics. I: State of research on mechanisms of action, effectiveness and compliance in treatment of psychoses].
Krausz M; Sorgenfrei T
Psychiatr Prax; 1991 Jan; 18(1):9-13. PubMed ID: 1674156
[TBL] [Abstract][Full Text] [Related]
4. [Compliance in therapy of schizophrenic patients with neuroleptics--an overview].
Mayer C; Soyka M
Fortschr Neurol Psychiatr; 1992 Jun; 60(6):217-22. PubMed ID: 1353747
[TBL] [Abstract][Full Text] [Related]
5. Drugs and the quality of life: the patient's point of view.
Diamond R
J Clin Psychiatry; 1985 May; 46(5 Pt 2):29-35. PubMed ID: 2859278
[TBL] [Abstract][Full Text] [Related]
6. Subjective experience and subjective response to neuroleptics in schizophrenia.
Rossi A; Arduini L; Stratta P; Pallanti S
Compr Psychiatry; 2000; 41(6):446-9. PubMed ID: 11086150
[TBL] [Abstract][Full Text] [Related]
7. Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia.
Hofer A; Rettenbacher MA; Edlinger M; Kemmler G; Widschwendter CG; Fleischhacker WW
Acta Psychiatr Scand; 2007 Nov; 116(5):354-61. PubMed ID: 17868428
[TBL] [Abstract][Full Text] [Related]
8. Subjective well-being and initial dysphoric reaction under antipsychotic drugs - concepts, measurement and clinical relevance.
Lambert M; Schimmelmann BG; Karow A; Naber D
Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S181-90. PubMed ID: 14677077
[TBL] [Abstract][Full Text] [Related]
9. [Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease].
Naber D; Lambert M; Karow A
Psychiatr Prax; 2004 Nov; 31 Suppl 2():S230-2. PubMed ID: 15586315
[TBL] [Abstract][Full Text] [Related]
10. [Patient modified medication: how do schizophrenic patients manage their neuroleptics?].
Hornung WP; Buchkremer G; Redbrake M; Klingberg S
Nervenarzt; 1993 Jul; 64(7):434-9. PubMed ID: 8103569
[TBL] [Abstract][Full Text] [Related]
11. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment.
Löffler W; Kilian R; Toumi M; Angermeyer MC
Pharmacopsychiatry; 2003 May; 36(3):105-12. PubMed ID: 12806568
[TBL] [Abstract][Full Text] [Related]
12. [Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications].
Misdrahi D; Llorca PM; Lançon C; Bayle FJ
Encephale; 2002; 28(3 Pt 1):266-72. PubMed ID: 12091789
[TBL] [Abstract][Full Text] [Related]
13. [Can psycho-education of chronic schizophrenic patients have a short-term effect on drug-related attitude and behavior?].
Hornung WP; Franzen U; Lemke R; Wiesemann C; Buchkremer G
Psychiatr Prax; 1993 Jul; 20(4):152-4. PubMed ID: 8103230
[TBL] [Abstract][Full Text] [Related]
14. [Psychological conditions of patient's decision to break off the treatment with atypical neuroleptic: a case study].
Murawiec S
Psychiatr Pol; 2000; 34(2):289-98. PubMed ID: 10974942
[TBL] [Abstract][Full Text] [Related]
15. Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride.
Linden M; Scheel T; Eich FX
J Psychopharmacol; 2006 Nov; 20(6):815-23. PubMed ID: 16401647
[TBL] [Abstract][Full Text] [Related]
16. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia.
Meltzer HY; Sommers AA; Luchins DJ
J Clin Psychopharmacol; 1986 Dec; 6(6):329-38. PubMed ID: 2879856
[TBL] [Abstract][Full Text] [Related]
17. Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication.
Rettenbacher MA; Burns T; Kemmler G; Fleischhacker WW
Pharmacopsychiatry; 2004 May; 37(3):103-9. PubMed ID: 15138893
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
Gaebel W; Möller HJ; Buchkremer G; Ohmann C; Riesbeck M; Wölwer W; Von Wilmsdorff M; Bottlender R; Klingberg S
Eur Arch Psychiatry Clin Neurosci; 2004 Apr; 254(2):129-40. PubMed ID: 15146342
[TBL] [Abstract][Full Text] [Related]
19. [New chemotherapy approaches to psychoses].
Olié JP; Baylé FJ
Encephale; 1997 Apr; 23 Spec No 2():2-9. PubMed ID: 9273302
[TBL] [Abstract][Full Text] [Related]
20. Factors which can make patients difficult to treat.
Kane JM
Br J Psychiatry Suppl; 1996 Dec; (31):10-4. PubMed ID: 8968650
[No Abstract] [Full Text] [Related]
[Next] [New Search]
